INTRODUCTION
============

Bipolar disorder (BD) has been considered a major risk factor for suicide \[[@b1-pi-2019-03-10],[@b2-pi-2019-03-10]\]. A systemic review has identified previous suicide attempts as a major factor for completed suicide in BD patients along with early onset, family history of suicide among first-degree relatives, and other factors \[[@b3-pi-2019-03-10]\]. Among 362 patients diagnosed with BD, based on the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision \[[@b4-pi-2019-03-10]\], patients with prior suicide attempt were characterized by polarity at onset, increased number of psychiatric hospitalization, psychiatric comorbidity, and treatment with lithium and polypharmacy (4 or more psychotropic drugs) compared to those without prior suicide attempts \[[@b5-pi-2019-03-10]\]. Moreover, the actigraphic findings revealed that the sleep and circadian rhythms of morning preference, vigorous circadian type, and earlier start of daily activity were potential trait differences in BD patients with suicide attempts from those without such attempts \[[@b6-pi-2019-03-10]\]. Similar to the studies based on other ethnicities, this study aimed to investigate clinical correlations of suicide attempts in Asian patients with BD, particularly in Koreans. The Research on Asian Psychotropic Prescription Pattern for Bipolar Disorder (REAP-BD) study is the largest ongoing international survey of psychotropic prescriptions for patients with BD in Asia. By using the Korean data from the REAP-BD study, we aimed to identify the lifetime suicide attempt-related patterns of clinical characteristics and psychotropic drug use in Koreans.

METHODS
=======

During the REAP-BD study period from September to December 2018, BD patients will be enrolled as study participants from 16 Asian countries or areas, including Bangladesh, China, Hong Kong, India, Indonesia, Japan, Korea, Malaysia, Myanmar, Pakistan, Philippines, Singapore, Sri Lanka, Taiwan, Thailand, and Vietnam. The research protocols and informed consent forms were approved by the institutional review boards of all survey centers under the direction of Taipei City Hospital, Taipei, Taiwan (receipt number: TCHIRB-10605117-E). The only inclusion criterion was a diagnosis of BD (F31) made using the International Classification of Diseases, tenth revision \[[@b7-pi-2019-03-10]\]. To reflect accurate clinical situations of Asian regions, the specific exclusion criteria were not defined. Moreover, 350 South Korean BD patients were enrolled in the study from 4 university-affiliated general hospitals, 2 psychiatric hospitals, and 1 veterans health service medical center. The recruited number of Korean subjects with BD in each of the 7 centers ranged from 30 to 100. Clinical psychiatrists of the survey centers collected information on demographic and clinical characteristics, which included the number of suicide attempts, rapid cycling, long-term course, compete blood cell count and blood chemistry findings, psychotropic prescription patterns. Before the survey, conferences were held to promote the consistency of data collection and entry. The data collection center was located at the Taipei City Psychiatric Center, Taipei, Taiwan.

We developed definitions of certain terms and used classifications as standards for the study. Suicide attempts were dichotomously evaluated as either its presence or absence in the REAP-BD study, although suicide attempts were subgrouped into the impulsive and planed patterns by a cluster analysis of 888 Korean suicide attempts \[[@b8-pi-2019-03-10]\]. Rapid cycling was defined as the presence of four or more episodes of BD within 1 year, based on the concept of Dunner and Fieve \[[@b9-pi-2019-03-10]\]. Seasonality was considered as patterns with peaks for manic episodes in spring-summer, peaks for depressive episodes in early winter, and peaks for mixed episodes in early spring and summer \[[@b10-pi-2019-03-10]\]. Body mass index (BMI) was calculated as weight (kg)/height (m)2. The use of psychotropic drugs were grouped according to the Anatomical and Therapeutic Chemical (ATC) Classification index of the World Health Organization Collaborating Center for Drug Statistics Methodology \[[@b11-pi-2019-03-10]\]. Because of the partly outdated groupings of the ATC Classification index, lithium and clonazepam were respectively grouped as a mood stabilizer and an anxiolytic.

We used *χ*^2^ tests for discrete variables and independent t-tests for continuous variables for our statistical analyses, and the patterns of clinical characteristics and psychotropic drug use were compared between BD patients with and without a history of suicide attempts. In addition, the potential effects of confounding factors were adjusted by using binary logistic analyses for discrete variables and analyses of covariance for continuous variables. Statistical significance was set at p\<0.05 (two-tailed) for all tests. All statistical analyses were conducted using IBM SPSS 24 (IBM Co., Armonk, NY, USA).

RESULTS
=======

After statistical analyses of 350 participants, 15.1% (n=53) of the subjects reported a history of suicide attempts. Moreover, 5.1% (n=18) and 2.9% (n=10) of patients reported attempting suicide within the past year and the past month, respectively. In terms of baseline characteristics, the proportion of outpatients was significantly smaller for BD patients with a history of suicide attempts rather than for those without such attempts (*χ*^2^=4.217, p=0.040). However, there were no statistically significant differences in age, sex, and employment. Age, sex, duration of illness, and enrollment as an outpatient were defined as the confounding factors, which could influence the clinical characteristics and psychotropic drug prescription patterns in lifetime suicide attempt subjects.

As shown in [Table 1](#t1-pi-2019-03-10){ref-type="table"}, adjusting the potential effects of confounding factors, participants with a history of suicide attempts presented a significantly more prevalent depressive episode \[adjusted odds ratio (aOR)=1.925, p=0.040\], less prevalent remission state (aOR=0.519, p=0.040), and lower levels of hemoglobin (F=5.924, p=0.016) than those without such attempts when the potential effects of the enrollment as an outpatient were adjusted. Furthermore, those with a history of suicide attempts used significantly more antidepressants (aOR=2.776, p=0.005), anxiolytics (aOR=1.920, p=0.045), and hypnotics (aOR=2.946, p=0.018) than those without. In contrast, there were no significant differences in the duration of BD, duration of untreated illness, current manic and mixed episode, duration of current episode, polarity at onset, rapid cycling in lifetime, seasonality in the past year, seasonality in lifetime, levels of BMI, white blood cell count, platelet count, total cholesterol and triglyceride, and uses of mood stabilizer, antipsychotic and anti-parkinsonian drugs between the two groups.

DISCUSSION
==========

In summary, our findings indicate that BD patients with a history of suicide attempts have a more prevalent depressive episode, less prevalent remission state, lower levels of hemoglobin, and more prescriptions for antidepressants, anxiolytics, and hypnotics compared to those without such attempts. A previous study has presented that suicidality is more prevalent in subjects with bipolar depression than in subjects with depressive mania and pure mania \[[@b12-pi-2019-03-10]\]. Also, subjects with bipolar depression who have with a history of suicide attempts have been noted to have reduced gray matter volumes in the dorsolateral prefrontal cortex, orbitofrontal cortex, anterior cingulate cortex, and superior temporal cortex, along with in other brain areas. Hence, an inability to plan goal-directed behavior has been proposed as an intervening variable between suicidality and bipolar depression \[[@b13-pi-2019-03-10]\]. Furthermore, circadian behavior in BD can be influenced by the CLOCK rs1801260 gene polymorphism: a study has shown that increased suicidality and depressive cognitive distortion is present in CLOCK rs1801260\*C carrier patients with bipolar depression \[[@b14-pi-2019-03-10]\]. Partly consistent with our findings, the relationship between previous suicide attempts and bipolar depression has been evidenced using several neurobiological correlates. The prevalence of anemia may differentiate chronic patients with BD or other psychiatric disorders from the general population, and it may also differentiate patients with schizophrenia from those with affective disorders; remarkably, an inverse relationship between hemoglobin level and a history of suicide attempts may be suggested by these findings \[[@b15-pi-2019-03-10],[@b16-pi-2019-03-10]\]. Such a relationship between hemoglobin levels and suicide attempts cannot be explained simply. By the findings of Wysokinski and Szczepocka \[[@b16-pi-2019-03-10]\], subnormal erythrocyte counts were more prevalent in patients with BD than in those with schizophrenia or unipolar depression. Since BD is linked to an imbalance of fluid homeostasis, we speculate that lower levels of hemoglobin in BD patients with a history of suicide attempts can be associated with the concentration changes in blood components that accompany manic episodes in BD. Moreover, it may be assumed that manic features could have intervening effects on an inverse relationship between hemoglobin levels and suicide attempts in BD patients. Furthermore, an increased risk of suicide attempts is positively correlated with the use of antidepressant, benzodiazepine, or valproic acid, according to a 3.5-year follow-up study for 826 inpatient with BD in Finland \[[@b17-pi-2019-03-10]\]. On the contrary, it might be assumed that antidepressants, anxiolytics, or hypnotics could be used to treat bipolar depression \[[@b18-pi-2019-03-10]\]. Regardless of the causality relationship between antidepressants, anxiolytics, or hypnotics and suicide attempts, the findings supported the notion that the use of antidepressants is controversial in the treatment of BD, including bipolar depression \[[@b19-pi-2019-03-10]\].

Our study has several limitations. First, because the REAP-BD study was not considered an epidemiological survey, generalization and extrapolation of our findings should be limited. Second, psychiatric comorbidity was not evaluated, and thus, its potential effects on the findings could not be adjusted. Third, although there was a consensus meeting before the initiation of our study, inter-rater reliability for evaluating clinical characteristics were not considered. Fourth, statistical significances may potentially not correspond to clinical ones. Despite these limitations, our findings are valuable in indicating the presence of lower levels of hemoglobin, more prevalent depressive episode, less prevalent remission state, and more use of antidepressants, anxiolytics, or hypnotics in Koreans with a history of suicide attempts than in those without such attempts. Our results also offer another reference in further interpretation or comparison for the overall data of Asians with BD in the REAP-BD study.
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Clinical characteristics and psychotropic prescription patterns of bipolar disorder patients with and without a history of suicide attempts

                                                                                        Total sample (N=350)   Lifetime suicidal attempt   Statistical coefficients   Unadjusted p-value   Adjusted p-value^[\*](#tfn1-pi-2019-03-10){ref-type="table-fn"}^   
  ------------------------------------------------------------------------------------- ---------------------- --------------------------- -------------------------- -------------------- ------------------------------------------------------------------ -------
  Age, mean (SD) years                                                                  43.6 (15.2)            45.0 (16.2)                 43.4 (15.0)                t=0.720              0.472                                                              \-
  Female, N (%)                                                                         210 (60.0)             32 (60.4)                   178 (59.9)                 χ^2^=0.004           0.951                                                              \-
  Employed, N (%)                                                                       63 (18.0)              8 (15.1)                    55 (18.5)                  χ^2^=0.357           0.550                                                              0.965
  Outpatient, N (%)                                                                     197 (56.3)             23 (43.4)                   174 (58.6)                 χ^2^=4.217           0.040                                                              \-
  Duration of illness, N (%)^[†](#tfn2-pi-2019-03-10){ref-type="table-fn"}^                                                                                           χ^2^=1.946           0.857                                                              \-
   \<6 months                                                                           22 (6.7)               2 (4.0)                     20 (7.2)                                                                                                           
   6--12 months                                                                         6 (1.8)                1 (2.0)                     5 (1.8)                                                                                                            
   1--5 years                                                                           50 (15.2)              9 (18.0)                    41 (14.7)                                                                                                          
   5--10 years                                                                          75 (22.9)              14 (28.0)                   61 (21.9)                                                                                                          
   10--20 years                                                                         87 (26.5)              12 (24.0)                   75 (27.0)                                                                                                          
   \>20 years                                                                           88 (26.8)              12 (24.0)                   76 (23.2)                                                                                                          
  Duration of untreated illness, N (%)^[‡](#tfn3-pi-2019-03-10){ref-type="table-fn"}^                                                                                 χ^2^=0.520           0.914                                                              \-
   \<6 months                                                                           115 (42.1)             17 (43.6)                   98 (41.9)                                                                                                          0.808
   6--12 months                                                                         53 (19.4)              6 (15.4)                    47 (20.1)                                                                                                          0.418
   1--5 years                                                                           70 (25.6)              11 (28.2)                   59 (25.2)                                                                                                          0.464
   \>5 years                                                                            35 (12.8)              5 (1.8)                     30 (12.8)                                                                                                          0.531
  Polarity at onset, N (%)^[§](#tfn4-pi-2019-03-10){ref-type="table-fn"}^                                                                                             χ^2^=0.794           0.373                                                              0.502
   Depressive episode                                                                   79 (32.0)              16 (38.1)                   63 (31.0)                                                                                                          
   Manic episode                                                                        166 (67.8)             26 (61.9)                   140 (69.0)                                                                                                         
  Current episode, N (%)                                                                                                                                                                                                                                      
   Depressive episode                                                                   36 (10.3)              13 (24.5)                   23 (7.7)                   χ^2^=13.730          \<0.0001                                                           0.040
   Manic episode                                                                        54 (15.4)              6 (11.3)                    48 (16.2)                  χ^2^=0.808           0.369                                                              0.313
   Mixed episode                                                                        16 (4.6                4 (7.5)                     12 (4.0)                   χ^2^=1.268           0.260                                                              0.241
   Remission                                                                            216 (61.7)             27 (50.9)                   189 (63.6)                 χ^2^=3.067           0.080                                                              0.040
  Duration of current episode, N (%)^[ǁ](#tfn5-pi-2019-03-10){ref-type="table-fn"}^                                                                                   χ^2^=4.484           0.345                                                              \-
   \<1 month                                                                            77 (24.2)              10 (21.3)                   67 (24.7)                                                                                                          0.122
   1--3 months                                                                          106 (33.3)             11 (23.4)                   95 (35.1)                                                                                                          0.973
   3--6 months                                                                          41 (12.9)              9 (19.1)                    32 (11.8)                                                                                                          0.078
   6--12 months                                                                         19 (6.0)               4 (8.5)                     15 (5.5)                                                                                                           0.085
   \>1 year                                                                             75 (23.6)              13 (27.7)                   62 (22.9)                                                                                                          0.099
  Rapid cycling in lifetime, N (%)                                                      11 (3.1)               3 (5.7)                     8 (2.7)                    χ^2^=1.300           0.254                                                              0.271
  Seasonality in lifetime, N (%)                                                        14 (4.0)               4 (7.5)                     10 (3.4)                   χ^2^=2.047           0.153                                                              0.618
  Body mass index, mean (SD) kg/m^2^                                                    24.3 (4.1)             23.8 (4.6)                  24.4 (4.0)                 t=-1.016             0.310                                                              0.275
  CBC and blood chemistries                                                                                                                                                                                                                                   
   White blood cell, mean (SD)×10^3^/uL                                                 6.6 (2.2)              6.5 (2.1)                   6.7 (2.3)                  t=-0.412             0.681                                                              0.839
   Hemoglobin, mean (SD) g/d                                                            13.2 (1.7)             12.5 (1.8)                  13.7 (1.6)                 t=-2.772             0.006                                                              0.016
   Platelet, mean (SD)×10^3^/u                                                          241.0 (59.3)           243.0 (63.4)                240.6 (58.7)               t=0.210              0.834                                                              0.954
   Total cholesterol, mean (SD) mg/dL                                                   181.2 (38.4)           174.3 (38.1)                182.9 (38.5)               t=-1.137             0.257                                                              0.248
   Triglyceride, mean (SD) mg/dL                                                        137.0 (105.6)          111.3 (52.3)                142.2 (112.8)              t=-1.224             0.223                                                              0.601
  Mood stabilizer, N (%)                                                                327 (93.4)             47 (88.7)                   280 (94.3)                 χ^2^=2.295           0.130                                                              0.092
  Antipsychotic, N (%)                                                                  317 (90.6)             47 (88.7)                   270 (90.9)                 χ^2^=0.262           0.609                                                              0.641
  Antidepressant, N (%)                                                                 64 (18.3)              17 (32.1)                   47 (15.8)                  χ^2^=7.949           0.005                                                              0.005
  Anxiolytic, N (%)                                                                     167 (47.7)             32 (60.4)                   135 (45.5)                 χ^2^=4.015           0.045                                                              0.045
  Hypnotic, N (%)                                                                       30 (8.6)               10 (18.9)                   20 (6.7)                   χ^2^=8.450           0.004                                                              0.018
  Anti-parkinson drug, n (%)                                                            45 (12.9)              9 (17.0)                    36 (12.1)                  χ^2^=0.948           0.330                                                              0.205

adjusted for potential effects of age, sex, enrollment as an outpatient and duration of illness,

N=328,

N=273,

N=245,

N=318.

CBC: complete blood cell count, SD: standard deviation
